Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Napoleone Ferrara

    TitleAdjunct Professor
    SchoolUniversity of California, San Diego
    DepartmentOphthalmology
    Address9500 Gilman Drive #0819
    CA La Jolla 92093
    Phone858-822-6822
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of Catania Medical SchoolM.D.

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Xin H, Zhong C, Nudleman E, Ferrara N. Evidence for Pro-angiogenic Functions of VEGF-Ax. Cell. 2016 Sep 22; 167(1):275-284.e6. PMID: 27662093.
        View in: PubMed
      2. Ferrara N. Commentary on "Humanization of an Anti-VEGF Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders". Cancer Res. 2016 Sep 01; 76(17):4913-5. PMID: 27587649.
        View in: PubMed
      3. Ferrara N. VEGF and Intraocular Neovascularization: From Discovery to Therapy. Transl Vis Sci Technol. 2016 Mar; 5(2):10. PMID: 26981332.
        View in: PubMed
      4. Liang W, Ferrara N. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis. Cancer Immunol Res. 2016 Feb; 4(2):83-91. PMID: 26839309.
        View in: PubMed
      5. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016 06; 15(6):385-403. PMID: 26775688.
        View in: PubMed
      6. Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, Day ES, Demeule B, Liu J, Shire SJ, Ferrara N, Yadav S. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014 Oct 6; 11(10):3421-30. PMID: 25162961.
        View in: PubMed
      7. Moriya J, Ferrara N. Inhibiting the response to VEGF in diabetes. Sci Signal. 2014 Jan 07; 7(307):pe1. PMID: 24399294.
        View in: PubMed
      8. Zhong C, Wang J, Li B, Xiang H, Ultsch M, Coons M, Wong T, Chiang NY, Clark S, Clark R, Quintana L, Gribling P, Suto E, Barck K, Corpuz R, Yao J, Takkar R, Lee WP, Damico-Beyer LA, Carano RD, Adams C, Kelley RF, Wang W, Ferrara N. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res. 2013 Aug 15; 19(16):4433-45. PMID: 23812669.
        View in: PubMed
      9. Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res. 2013 Jul 1; 19(13):3681-92. PMID: 23685835.
        View in: PubMed
      10. Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol. 2012 Aug; 227(4):417-30. PMID: 22611036.
        View in: PubMed
      11. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun. 2011 May 06; 408(2):276-81. PMID: 21501594.
        View in: PubMed
      12. Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol. 2011; 55(4-5):383-8. PMID: 21858763.
        View in: PubMed
      13. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med. 2010 Oct; 16(10):1107-11. PMID: 20930754.
        View in: PubMed
      14. Yeung YA, Wu X, Reyes AE, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, Ferrara N, Lowman HB. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 2010 Apr 15; 70(8):3269-77. PMID: 20354184.
        View in: PubMed
      15. O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res. 2009 Nov 01; 15(21):6674-82. PMID: 19861458; PMCID: PMC4688942.
      16. Ferrara N. Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara by Kristin H. Kain. Dis Model Mech. 2009 Jul-Aug; 2(7-8):324-5. PMID: 19553691.
        View in: PubMed
      17. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009 Jan 06; 15(1):21-34. PMID: 19111878.
        View in: PubMed
      18. Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 2008 Jul 15; 68(14):5501-4. PMID: 18632597.
        View in: PubMed
      19. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008 Mar 13; 358(11):1129-36. PMID: 18337603; PMCID: PMC3030578.
      20. Campa C, Kasman I, Ye W, Lee WP, Fuh G, Ferrara N. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci. 2008 Mar; 49(3):1178-83. PMID: 18326747.
        View in: PubMed
      21. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008 Feb; 49(2):522-7. PMID: 18234994.
        View in: PubMed
      22. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct; 26(8):859-70. PMID: 17031284.
        View in: PubMed
      23. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69 Suppl 3:11-6. PMID: 16301831.
        View in: PubMed
      24. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem. 2006 Jan 13; 281(2):951-61. PMID: 16278208.
        View in: PubMed
      25. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol. 2005 Nov; 2(11):562-77. PMID: 16270097.
        View in: PubMed
      26. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29; 333(2):328-35. PMID: 15961063.
        View in: PubMed
      27. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005 Feb 01; 65(3):671-80. PMID: 15705858.
        View in: PubMed
      28. Tang K, Breen EC, Gerber HP, Ferrara N, Wagner PD. Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics. 2004 Jun 17; 18(1):63-9. PMID: 15084712.
        View in: PubMed
      29. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May; 3(5):391-400. PMID: 15136787.
        View in: PubMed
      30. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003 Aug; 4(2):133-46. PMID: 12957288.
        View in: PubMed
      31. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003 Mar 07; 112(5):645-57. PMID: 12628185; PMCID: PMC4480774.
      32. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002 Dec; 29(6 Suppl 16):10-4. PMID: 12516033.
        View in: PubMed